1-5 of 5
Harm Van Tinteren
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3 -ITD/ NPM1 wt Patients - a Study By the NOPHO-DB-SHIP Consortium

Gertjan J.L. Kaspers, Noa E. Wijnen, Joost B. Koedijk, Sae Ishimaru, Renske Benedictus, Ellen C. Van Opstal, Harm Van Tinteren, C. Michel Zwaan, Noha Biserna, Pamela Downs, Yvonne Duong, Yasser Mostafa Kamel, Jonas Abrahamsson, Nira Arad-Cohen, Nicole Bodmer, Luis Castillo, Daniel Cheuk, Vitor Costa, Barbara De Moerloose, Jose Maria Fernandez Navarro, Linda Fogelstrand, Bianca F. Goemans, Henrik Hasle, Olafur G. Jonsson, Zhanna Kovalova, Monica C. Munthe-Kaas, Ulrika Norén-Nyström, Sauli Palmu, Ramune Pasauliene, Kadri Saks, Anne Maria Tierens, Dominik Turkiewicz, Cornelis Jan Pronk
Journal: Blood
Blood (2023) 142 (Supplement 1): 1532.
https://doi.org/10.1182/blood-2023-181792
Published: 2023
Journal Articles

ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Sae Ishimaru, Gwenaëlle Gueguen, Seth E. Karol, Francisco J. Bautista Sirvent, Valeria Ceolin, Bianca F. Goemans, Marlous Bakker, Laura Di Laurenzio, Jennifer Lukin, Harm Van Tinteren, Gauri B. Sunkersett, Maika Onishi, Kristina Unnebrink, Dirk Reinhardt, Gwen L Nichols, E. Anders Kolb, C. Michel Zwaan
Journal: Blood
Blood (2022) 140 (Supplement 1): 3369–3370.
https://doi.org/10.1182/blood-2022-168818
Published: 2022
Journal Articles

Fludarabine Exposure Predicts Outcome after CD19 CAR T Cell Therapy in Children and Young Adults with Acute Leukemia; An Exploratory, Observational Study

Linde Dekker, Friso Calkoen, Yilin Jiang, Hilly Blok, Maike Spoon, Rick Admiraal, Peter Hoogerbrugge, Britta Julia Vormoor, Josef Vormoor, C. Michel Zwaan, Henk Visscher, Marc Bierings, Marieke Van Der Vlugt, Harm Van Tinteren, A. Laura Nijstad, Kim Van Der Elst, Alwin D. R. Huitema, Rob Pieters, Caroline Lindemans, Stefan Nierkens
Journal: Blood
Blood (2021) 138 (Supplement 1): 3871.
https://doi.org/10.1182/blood-2021-146450
Published: 2021
Journal Articles

A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients

Edoardo Pennesi, Erica Brivio, Marieke E. Willemse, Alwin D. R. Huitema, Saurabh Chandra, Ashwini Vijayakumar, Vincent H.J. Van Der Velden, H. Berna Beverloo, Chandra Durairaj, Andrea Viqueira, Antonella Ingrosso, Franco Locatelli, Jayashree Motwani, Jean-Pierre Bourquin, Francisco J. Bautista Sirvent, Carmelo Rizzari, Arnaud Petit, Donna Lancaster, Markus Metzler, Yves Bertrand, Laura Murillo-Sanjuán, Andrew J. Bukowkinski, Julie Krystal, Inge M. Van Der Sluis, Michael E. Roth, Harm Van Tinteren, Nobuko Hijiya, Christian M. Zwaan
Journal: Blood
Blood (2021) 138 (Supplement 1): 2558.
https://doi.org/10.1182/blood-2021-145709
Published: 2021
Journal Articles

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

Anton Hagenbeek, MD PhD, Josée M Zijlstra, MD, Wouter J Plattel, MD, Franck Morschhauser, MD, Petronella J Lugtenburg, MD PhD, Pauline Brice, MD, Martin Hutchings, MD, Thomas Gastinne, MD, Roberto D Liu, Coreline N Burggraaf, MD, Marcel Nijland, MD, Sanne H Tonino, MD PhD, Harm van Tinteren, MSc, Marta I Lopez Yurda, MSc, Marie José Kersten, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2923.
https://doi.org/10.1182/blood-2018-99-112235
Published: 2018